$AMRI (Albany Molecular Research Inc.)

$AMRI {{ '2016-08-24T11:50:19+0000' | timeago}} • Announcement

$AMRI said it entered into a non-exclusive commercial license agreement with Broad Institute of MIT and Harvard for use of CRISPR-Cas9 gene editing technology and has completed several projects for its customers. The company will continue to use technology to enhance its drug discovery service offerings and internal research and development.

$UNH {{ '2017-10-17T19:30:35+0000' | timeago}} • Announcement

$UNH is the first firm amongst its peers to report earnings every quarter. For the first time in its history, it is on track to cross revenues of $200Bil in 2017. 3Q revenues jumped 9% to $50.3Bil. $UNH's withdrawal from ACA individual insurance markets, along with a health insurance tax deferral, reduced revenues by $1.6Bil and growth rate by 4%.

$UNH {{ '2017-10-17T17:16:02+0000' | timeago}} • Announcement

$UNH reported 26% jump in its profits aided by strong growth in its Optum business. This is the first quarter the health insurer is reporting results under the helm of new CEO Dave Wichmann, who replaced Steve Hemsley in September. The company also raised its outlook for 2017. It now expects GAAP EPS to touch $9.45 and adjusted EPS to reach $10.

$MYL {{ '2017-10-17T16:40:23+0000' | timeago}} • Announcement

$MYL announced that the United States District Court for the Eastern District of Texas issued a decision finding all asserted claims of the patents relating to Restasis invalid. The Court recognized that $AGN's patent protection for Restasis ended in 2014.

$UNH {{ '2017-10-17T11:55:37+0000' | timeago}} • Infographic

$UNH UnitedHealth Earnings AlphaGraphics: Q3 2017 Highlights

$AGN {{ '2017-10-16T21:26:34+0000' | timeago}} • Announcement

Drugmaker $AGN gets an adverse effect from the U.S. District Court for the Eastern District of Texas. The judge invalidated Allergan's Restasis patent deal, which was signed with the Mohawk Tribe in the last month. Allergan plans to appeal the ruling. Restasis, a dry-eye treatment drug,  generated $1.5Bil of revenues for Allergan in 2016.

$MDT {{ '2017-10-16T20:09:05+0000' | timeago}} • Announcement

$MDT said its Medtronic Care Management Services (MCMS) business and American Well entered into a strategic partnership. Under the agreement, the businesses will work together to enable patient access to American Well's telemedicine services on MCMS' video-enabled platforms, and to allow bi-directional data flow between the two parties.

$REGN {{ '2017-10-16T14:56:28+0000' | timeago}} • Announcement

$REGN and $SNY announced positive results from a Phase 2 study of dupilumab in adults with active moderateto-severe eosinophilic esophagitis (a condition that causes swallowing difficulty). The study showed that patients who received dupilumab weekly reported a significant improvement in the ability to swallow versus placebo.

$REGN {{ '2017-10-16T13:04:52+0000' | timeago}} • Announcement

$REGN and Sanofi announced positive results from a Phase 2 investigational study of dupilumab in adults with active moderate-to-severe eosinophilic esophagitis. Eosinophilic esophagitis is a chronic, allergic inflammatory disease that damages the esophagus and prevents it from working properly, leading to difficulties swallowing and food impaction.

$AGN {{ '2017-10-12T22:44:22+0000' | timeago}} • Announcement

$AGN, which inked a controversial patent deal with Mohawk Tribe, reached a patent litigation settlement on its dry eye treatment drug Restasis with InnoPharma, a unit of $PFE. The litigation, which was filed in Sept. 2015 by Allergan, will be withdrawn and Allergan will grant license to InnoPharma to market Restasis from Feb. 2024 or earlier.

$AGN {{ '2017-10-10T18:02:39+0000' | timeago}} • Announcement

FDA accepts to review $AGN's New Drug Application seeking approval for ulipristal acetate, an investigational drug for the treatment of abnormal bleeding in women with uterine fibroids. Allergan expects the action date to occur in 1H18. According to the Agency for Healthcare Research and Quality (AHRQ), 26MM women in U.S. have got uterine fibroids.

$VRX {{ '2017-10-10T14:50:38+0000' | timeago}} • Infographic

$VRX's progress towards paying down a huge debt of $5Bil before Feb 2018.

$DEPO {{ '2017-10-10T13:44:58+0000' | timeago}} • Announcement

$DEPO said that as a result of the disruption to manufacturing operations in Puerto Rico due to Hurricane Maria, it is experiencing temporary delays in packaging and delivery of certain dosage strengths of NUCYNTA ER at the facility in Puerto Rico. Consequently, $DEPO expects its 4Q17 product revenue to be negatively impacted by less than $10MM.

$Q {{ '2017-10-10T12:37:04+0000' | timeago}} • Announcement

$Q announced the pricing of the offering of €420MM in gross proceeds of senior notes to be issued by its subsidiary, Quintiles IMS Incorporated. The notes will bear interest at a rate of 2.875% and will pay interest semi-annually in arrears on March 15 and Sept 15 of each year, beginning on March 15, 2018. The notes will mature on Sept 15, 2025.

$Q {{ '2017-10-10T12:14:55+0000' | timeago}} • Announcement

$Q announced the launch of an underwritten, secondary public offering of 9MM common shares by certain of its existing stockholders, including affiliates of TPG Global, CPP Investment Board Private Holdings, investment funds associated with Bain Capital Investors, and Leonard Green & Partners. $Q plans to repurchase from underwriter 4MM shares.

$REGN {{ '2017-10-05T17:28:07+0000' | timeago}} • Announcement

Sanofi and $REGN said the U.S. Court of Appeals for the Federal Circuit has ordered new trial and vacated permanent injunction in the dispute concerning $AMGN's asserted patent claims for antibodies targeting PCSK9. This ruling means that Sanofi and $REGN will continue marketing, selling and manufacturing Praluent (alirocumab) injection in the U.S.

$JNJ {{ '2017-10-05T13:58:49+0000' | timeago}} • Announcement

Animas Corp., a $JNJ Diabetes Care Companies, plans to discontinue the manufacturing and sale of Animas Vibe and OneTouch Ping insulin pumps, close operations and exit the insulin pump business. Animas has selected $MDT as its partner-of-choice to facilitate a seamless transition for patients, caregivers and healthcare providers.

$HRC {{ '2017-10-05T12:06:47+0000' | timeago}} • Announcement

Chairman of $HRC Board Rolf Classon will not stand for re-election to the BoD when his current term expires on March 6, 2018. The Board plans to appoint current independent director William Dempsey to this role if he is re-elected by shareholders. The company also elected Gary Ellis, retired CFO and SVP of $MDT, to its BoD, effective Oct 5, 2017.

$CRL {{ '2017-10-04T15:17:39+0000' | timeago}} • Announcement

$CRL and Trax, a subsidiary of MarketAxess Holdings, Inc., have agreed to integrate Trax’s MiFID II Trade and Transaction reporting solutions into the Charles River Investment Management Solution. This will help clients of both firms to use the Trax Approved Publication Arrangement to publish trade reports and transaction report trades.

$AGN {{ '2017-10-02T17:04:07+0000' | timeago}} • Announcement

FDA accepts to do a priority review of $AGN's antibiotic drug Avycaz. The supplemental New Drug Application (sNDA) filed by Allergan seeks to expand the usage of Avycaz for the treatment of patients with hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. The FDA is expected to take action on the filing in 1Q18.

$REGN {{ '2017-10-02T12:04:30+0000' | timeago}} • Announcement

Pharma company $REGN has entered into collaborations with the Biomedical Advanced Research & Development Authority to develop  treatments for infectious diseases. The first collaboration is focused on development of antibodies targeting up to 10 pathogens, while the second builds on a prior agreement to develop a potential therapy for Ebola virus.

Recent Transcripts

UNH (UnitedHealth Group Incorporated)
Tuesday, October 17 2017 - 12:45pm
ACET (Aceto Corp.)
Friday, August 25 2017 - 1:00pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
XON (Intrexon Corporation)
Wednesday, August 9 2017 - 9:30pm
MDCO (The Medicines Company)
Wednesday, August 9 2017 - 12:30pm
CRL (Charles River Laboratories International, Inc.)
Wednesday, August 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
DEPO (DepoMed Inc.)
Monday, August 7 2017 - 8:30pm
WCG (WellCare Health Plans, Inc.)
Friday, August 4 2017 - 1:00pm
CBM (Cambrex Corporation.)
Friday, August 4 2017 - 12:30pm
USPH (US Physical Therapy Inc.)
Thursday, August 3 2017 - 2:30pm
Q (Quintiles Transnational Holdings Inc.)
Thursday, August 3 2017 - 1:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
EXEL (Exelixis, Inc.)
Wednesday, August 2 2017 - 9:00pm
OSUR (OraSure Technologies, Inc.)
Wednesday, August 2 2017 - 9:00pm
CAH (Cardinal Health, Inc.)
Wednesday, August 2 2017 - 12:30pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, August 1 2017 - 9:00pm
INCY (Incyte Corporation)
Tuesday, August 1 2017 - 2:00pm
SNMX (Senomyx Inc.)
Thursday, July 27 2017 - 9:00pm

AlphaGraphics you may like